Although it has been generally accepted that porcine reproductive and respiratory syndrome virus (PRRSV) induces weak and delayed protective immunity after infection, it is unclear that the same immunological features can be applicable to all PRRS viruses because huge genetic variation exists even among the same genotypes of PRRSV (Type 1 and 2). In the current study, two genetically distinct type 2 PRRSV strains (VR-2332 and JA142) which showed approximately 90% nucleotide homology based on ORF5 sequences were characterized by both in vitro and in vivo assessments to determine the immunological features of the viruses. For in vitro assessment, porcine alveolar macrophages (PAM) were infected with the viruses at 10 −3 multiplicity of infection (MOI) and then supernatants and cells
INTRODUCTION
Porcine reproductive and respiratory syndrome (PRRS) is characterized by reproductive disorder in breeding animals and respiratory distress in all ages of pigs (Bilodeau et al, 1991; Goyal, 1993) . Its emergence was first reported in the United States in 1987 (Keffaber, 1989 and subsequently reported in Europe in 1990 (Paton et al, 1991) . Isolation of PRRS virus (PRRSV), the causal agent of the disease, was first reported in Europe in 1991 and later in North America in 1992 . Since then, the virus has been identified in most of pig-producing regions worldwide and has caused significant economic losses in swine industries (Dea et al, 1992; Paton et al, 1992; Murakami et al, 1994) . PRRSV is a member of the family Arteriviridae in the order Nidovirales (Cavanagh, 1997) and an enveloped virion containing a single-stranded positive-sense RNA genome. PRRSV has been classified into two genetically and antigenically distinct groups, European (Type 1) and North American (Type 2) genotype (Meng et al, 1995; Murtaugh et al, 1995) . Remarkable genetic and antigenic variations have been observed between the genotypes and within the same genotype (Yang et al, 1999; Cheon and Chae, 2000; Key et al, 2001; Forsberg et al, 2002; Pesch et al, 2005; Fang et al, 2007; Zhou et al, 2009 ). Such genetic and antigenic variation has hampered effective prevention and control of PRRS.
In general, PRRSV induces anti-inflammatory cytokines (Suradhat et al, 2003; Charerntantanakul et al, 2006; Gimeno et al, 2011; Dwivedi et al, 2012) and weak proinflammatory cytokines (López -Fuertes et al, 2000; Thanawongnuwech et al, 2004) . Thus, it stimulates delayed and weak protective immunity [i.e., serum virus neutralizing (SVN) antibody and interferon (IFN)-γ secreting T cells] which seldom appears until 3 to 4 weeks after infection (Meier et al, 2003; Faaberg et al, 2006; Vanhee et al, 2009 ). Passively acquired SVN antibody alone was proven to prevent viremia and reproductive failure in pigs challenged with virulent PRRSV strains (Osorio et al, 2002) , suggesting the critical role of SVN antibody in the control of virus infection. Nonetheless, cell-mediated immunity (CMI) appears to be essential for the clearance of PRRSV since PRRSV has been detected in lungs and lymph nodes despite the presence of SVN antibodies in serum or bronchoalveloar lavage fluid (Wills et al, 1997; Labarque et al, 2000; Bierk et al, 2001 ). The mechanisms for the weak induction of protective immunity by PRRSV have been explored in previous studies. The structural and non-structural proteins (nsp) are believed to modulate host immune responses (Wang et al, 2009 ). It has been recently shown that nsp1 of PRRSV modulates the expression of type I interferon (Beura et al, 2010; Beura et al, 2012; Chen et al, 2010; Wang et al, 2013; Kim et al, 2010) and TNF-α , which leads to persistent infection (Lamontagne et al, 2003) . In addition, PRRSV infects and destroys porcine alveolar macrophage (PAM), which is an active producer of cytokines and leukotrienes and has important roles in inducing pro-and anti-inflammatory responses in the alveolus (Gordon and Read, 2002) and innate immune response against respiratory infections (Pribul et al, 2008) .
As described above, the weak and delayed protective immunity after PRRSV infection has been reported by many previous studies, it is still unclear that the same immunological features can be applicable to all PRRS viruses because huge genetic variation exists among PRRSV strains and only a few PRRSV strains have been well characterized for their immune responses after infection. In the current study, two genetically distinct type 2 PRRS viruses (VR-2332 and JA142) which showed approximately 90% nucleotide homology based on ORF5 sequences were characterized by both in vitro and in vivo assessments to determine the immunological features of the viruses.
MATERIALS AND METHODS

Cells and viruses
PAM cells were harvested from ten, 6-week old, PRRS negative pigs as described. Pigs were euthanized and the lungs along with trachea and bronchus were aseptically collected from pigs. The lungs were lavaged thrice with 0.01 M phosphate buffer saline (PBS, pH 7.4) and the harvested wash fluid was centrifuged for 10 minutes at 1,000×g. The resulting pellet was washed three times with PBS and resuspended in 5 mL of PBS. To evaluate cell viability, the cells were diluted 100 times in PBS and mixed with 0.4% trypan blue in 1：1 ratio and counted by the Countess TM Automated Cell Counter (Invitrogen, Carlsbad, CA, USA). After counting, cells adjusted to 5×10 7 /mL were dispensed in cryovials and saved in −80 o C until used. For culturing PAM, the cells were briefly thawed in a waterbath at 37 o C with gentle stirring and diluted 10 times in RPMI-1640 (Sigma Aldrich, St. Louis, USA) containing 10% FBS, 1% L-glutamine and 1% antibiotics (10,000 units/mL of penicillin, 10,000 μg/mL of streptomycin, and 25 μg/mL of Amphotericin B) (Gibco, Carlsbad, CA, USA) so as to maintain a final cell number of 5×10 following the manufacturer's instructions. RNA was reverse transcribed into cDNA using high-capacity cDNA reverse transcription kits (Applied Biosystems, Foster city, CA) and real-time polymerase chain reaction (PCR) was then performed on a 7500 Fast Real-time PCR system (Applied Biosystems) using various cytokine specific primers by following the manufacturer's instructions. Primer sequences used in this study are shown in Table  1 . Ten μL of 2× Power SYBGR (Applied Biosystems), 2 μL of cDNA and 1 μL of each forward primer (10 pm/μL) and reverse primer (10 pm/μL) were used for PCR amplification. All the samples were tested in duplicate and the cycling conditions were as follows: (a 
Quantitative PCR for virus titration
The virus titers in the supernatant and PAM cell lysates were measured by a real-time reverse transcriptionpolymerase chain reaction (RT-PCR) using TaqMan 
Animal study
A total of 15, three-week-old PRRSV-free pigs were randomly divided into 3 groups and housed separately. After acclimated for 3 days, 5 pigs in each group were challenged with VR2332, JA142 (2 mL of 10 3 TCID50/ mL per pig) or sham inoculum (RPMI-1640) and housed for 6 weeks. All pigs were bled at 0, 7, 14, 21, 28, 35 and 42 days post challenge (dpc). Sera were separated immediately after bleeding and stored in a −80 o C freezer until used. 
ELISA
All collected sera were tested by a commercial ELISA kit (Anigen PRRS Ab ELISA 4.0, Bionote, Hwasung, Korea) as per the manufacturer's instructions to determine IgG antibody specific for nucleocapsid protein of PRRSV (both type 1 and type 2).
Virus neutralization assay
Fluorescent focus neutralization (FFN) assay was performed to assess the titer of SVN antibodies in the sera as previously described (Kim and Yoon, 2008) . The serum samples were first heat inactivated at 56 o C for 45 min and then 2-fold serially diluted with RPMI-1640 medium growth medium. One hundred μL of each diluted serum were mixed with an equal volume of PRRSV (VR2332 or JA142) at 10 3 fluorescent focus forming unit per mL (FFU/mL). The mixtures were incubated at 37 o C for 1 hr in a humidified atmosphere with 5% CO2 and then transferred into MARC-145 cell monolayers prepared in 96-well plates (Corning Inc., Corning, NY, USA) and incubated for another 1 hr at 37 o C in a humidified atmosphere with 5% CO2 supply. After the removal of the inoculum, cells were replenished with 200 μL of fresh RPMI-1640 growth medium per well and further incubated at 37 o C for 20 hr. Afterwards, cells were fixed with ice cold 80% acetone aqueous solution for 5 min. The acetone was removed and cells were air dried for 30 min. Then, cells were reacted with 1：10000 diluted PRRSV nucleocapsid specific monoclonal antibody SDOW-17 (Rural Technologies, Brookings, SD, USA) and stained with 1：250 diluted fluorescein isothiocyanate (FITC) labeled goat an- ti-mouse IgG (H+L) (KPL, Gaithersburg, MD, USA). Before observation under an invert fluorescent microscope, plates were washed three times with PBS and then number of virus-specific fluorescent foci in each well was counted. SVN antibody titer was expressed as reciprocal of the highest dilution in which 90% or higher reduction in the number of FFU was observed.
Data Analysis
Statistical analysis was done by SPSS Advanced Statistics 17.0 (SPSS Inc., Chicago, USA). The cytokine induction by each virus in PAM was compared with that by VR2332 using Man Whitney U test. The repeated measurements of viremia and PRRSV nucleocapsid-specific antibody levels in the challenged pigs were analyzed using repeated measures ANOVA to determine the overall difference and pairwise comparisons between groups.
RESULTS
Different PRRSV strains displayed various levels of transcriptional activation of cytokines PAM cells were infected with JA142 or VR2332 and the transcriptional activation of cytokines, viz. TNF-α, IFN-α, IFN-β was measured by real-time PCR. JA142 induced a significantly higher mRNA expression of IFN-α, IFN-β and TNF-α (Fig. 1) compared with mock or VR2332 though the mRNA accumulation of TNF-α and IFN-β induced by VR2332 was also significantly higher compared with mock. Other cytokines, viz. IL-1α and IL-12 did not display any significant differences in their levels induced by either of viruses.
Viral titers in the supernatants and PAM cell lysates
Viral titers detected from PAM cell lysates (Fig. 2) did not show any significant differences between JA142 and VR2332 infected cells, however, the viral titers in the supernatants (Fig. 2) were significantly higher in JA142-infected cells when compared with VR2332-infected cells.
Viremia levels after challenge with JA142 or VR2332
Viremia was detected in all of the sera collected from the challenged pigs at 7 dpc (Fig. 3) when most viruses reached their highest titer. The mean levels of viremia in the pigs challenged with VR2332 or JA142 were 4.6 or 5.2 log10 TCID50/mL, respectively. At 42 dpc, the last bleeding time point, viremia was not detected in most of the challenged pigs. There were no significant differences in viremia levels between the groups challenged with JA142 or VR2332.
PRRSV nucleocapsid-specific antibody responses Pigs seroconverted to PRRSV at 2 weeks after the exposure to PRRSV and remained seropositive until the end of the study (Fig. 4) . The negative control group remained seronegative until the end of the study. No significant difference was observed between the groups challenged with JA142 or VR2332.
The induction of SVN antibodies after challenge
Levels of SVN antibodies in collected serum samples were determined by FFN. At 42 dpc (the last bleeding time point), only homologous SVN antibody was induced and no significant cross-neutralizing antibody was induced either by VR2332 or JA142 (Fig. 5) . However, JA142 induces significantly higher levels of homologous SVN antibodies (1：4 to 1：32) as compared with VR2332 (＜1：4).
DISCUSSION
The aberrant immune response by PRRSV infection has been one of the major hurdles in understanding the immunobiology of PRRS. Although it is known that PRRSV primarily replicates in PAM Wensvoort et al, 1992) , local and systemic immune responses mediated by PAM infected with various PRRSV strains remains largely unexplored. In the present study, the immunological features of two genetically distinct type 2 PRRSV strains were characterized by in vitro and in vivo assessments. Even though the two strains showed approximately 90% nucleotide homology based on ORF5 sequences, the transcriptional activation of various cytokines induced by these two PRRSV strains varied significantly; VR2332 induced significantly lower mRNA expression of INF-α/β and TNF-α than JA142 in PAM though it induced still higher levels of IFN-β and TNF-α expression compared with mock controls. In special, VR2332 failed to induce a significant expression of INF-α, an important type I interferon and it might indicate that weak protective immune responses induced by VR2332 could be resulted from poor type I interferon expression after VR2332 infection. The differential cytokine expression levels induced by JA142 and VR2332 is in agreement with a recently published report demonstrating that various PRRSV isolates induce different cytokine-expression profiles on antigen presenting cells (Gimeno et al, 2011) .
In animal study, there were no differences in viremia and nucleocapsid-specific antibody levels detected from the pigs infected with either JA142 or VR2332 until 42 dpc, suggesting that JA142 and VR2332 replicate equally well and produce similar levels of non-virus neutralizing antibody (i.e., nucleocapsid-specific antibody) upon infection. However, the pigs infected with JA142 produced significantly higher levels of SVN antibody at 42 dpc as compared with those infected with VR2332. Because JA142 induced also higher levels of pro-inflammatory cytokine than VR2332 in PAM after infection, it was speculated that different expression levels of pro-inflammatory cytokines in PAM could play an important role in the production of SVN antibodies and protective immune responses.
The present study gives an insight into the differential immunological features of two PRRSV strains though genetic determinants and mechanisms for the modulation of host immune response by PRRSV should be explored further in the future. In addition, the current study could be useful in classifying PRRSV based on immunological characteristics and selecting candidate strains for vaccine development against PRRSV.
